Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Imiglucerase · Cerezyme

Recombinant protein · Protein replacement: glucosylceramidase (beta-glucocerebrosidase) (GBA1) · developed by Genzyme

Approved FDA, May 1994
SNY Developer
1 Registered trials

What is Imiglucerase?

Imiglucerase is a recombinant lysosomal glucocerebrosidase enzyme. It catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, and its mannose sugars mediate uptake by cells such as macrophages. It is used in Gaucher disease, a deficiency of this enzyme that causes glucocerebroside accumulation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cerezyme
Drug type
Recombinant protein
Targets
glucosylceramidase (beta-glucocerebrosidase) (GBA1)
Mechanism
Protein replacement: glucosylceramidase (beta-glucocerebrosidase) (GBA1)
Pathways
glucocerebroside hydrolysis, lysosomal glycosphingolipid catabolism
Therapy area
Neurology
Developer
Genzyme (SNY)
FDA status
Approved as Cerezyme (May 23, 1994), BLA020367 · FDA label
UNII
Q6U6J48BWY

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 27, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07927140 Phase 3 Gaucher's Disease Type III Not yet recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gaucher's Disease Type III

More from Genzyme

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Imiglucerase

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.